Correction to: Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China

Authors requested an adjustment to the results of the model following an error identified in price data which implicates the incremental cost-effectiveness values calculated. As such,  corrections have been made to the original article. The conclusion and direction of the study remain unchanged following these modifications. The errors are given below:

In the Methods of the Abstract section a sentence has been updated to: The corresponding total costs were CNY 7721 (USD 1120), CNY 9578 (USD 1388) and CNY 9481 (USD 1375). Comparing to both comparisons, the incremental cost-effectiveness (ICER) of linaclotide was CNY 29643 (USD 4298) per quality-adjusted life year (QALY), CNY 2417 (USD 350) per QALY, respectively.

In Table 2, under the cost, there is a correction to the Linaclotide value, the correct value is CNY 360.64 (USD 52.29).

In the Results section, under the Base-case analysis, the corrected text is given as: From the perspective of society, the result showed that the total cost of linaclotide was CNY 9578 (USD 1388) with 0.821 gains in QALY. The total cost of PEG was CNY 8797 (USD 1276) with 0.795 QALYs gains, while the total cost of lactulose was CNY 9481 (USD 1375) with 0.781 QALY gains. Comparing to both comparisons, the incremental cost-effectiveness(ICER) of inaclotide was CNY 29643 (USD 4298) per quality-adjusted life yea (QALY), CNY 2417 (USD 350) per QALY, respectively.

Changes were also made to Table 3.

Table 3 Base-case analysis (cost: CNY 1 = USD 0.145, Health Outcome: QALYs)

An amendment was also made in the Scenario section; Linaclotide remained to be cost-effective over the 2-year period compared with PEG and lactulose (Table 4). Changes were also madee in the Discussion section: Selection of linaclotide would increase QALYs gained while increasing costs compared with PEG or lactulose.

The results suggest that linaclotide is cost-effective, suggesting it as a suitable drug to implement.

Corrections were also implemented in Table 4.

Table 4 Scenario analysis for 2 years (cost: CNY 1 = USD 0.145, Health Outcome: QALYs)

Finally, a correction was made in the Conclusion section: When compared with PEG and lactulose, linaclotide is considered to be a cost-effective strategy for the treatment of IBS-C in China, providing more QALY gains and increasing total cost.

留言 (0)

沒有登入
gif